BNT111 (BioNTech) — an investigational cancer immunotherapy — uses a fixed combination of mRNA-encoded, tumor-associated antigens designed to activate a precise and strong immune response against cancer.
Publications
Correlation of CCL8 expression with immune cell infiltration of skin cutaneous melanoma: potential as a prognostic indicator and therapeutic pathway
The tumor microenvironment (TME) is critical in the progression and metastasis of skin cutaneous melanoma (SKCM).
Metastatic melanoma concurrent to the urinary bladder and endometrium: Case report
We report a case of a 47-year-old woman with a history of acral lentiginous melanoma, left great toe subungual primary, metastatic to the lungs, brain, and spleen, presenting with lower urinary tract symptoms.
FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR
The FDA has approved pembrolizumab (Keytruda) for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection (CR).